- Home
- NFE vs RLMD Comparison
NFE vs RLMD Comparison
Compare NFE & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NFE | RLMD |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.4M | 319.7M |
| IPO Year | 2018 | 2012 |
Fundamental Metrics
Financial Performance| Metric | NFE | RLMD |
|---|---|---|
| Price | $0.59 | $6.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $7.70 | ★ $12.40 |
| AVG Volume (30 Days) | ★ 20.3M | 2.0M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.28 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,364,860,000.00 | $13,070.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $89.10 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $0.56 | $0.24 |
| 52 Week High | $7.05 | $7.41 |
Technical Indicators
Market Signals| Indicator | NFE | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 27.37 | 60.04 |
| Support Level | $0.56 | $3.49 |
| Resistance Level | $1.38 | $7.41 |
| Average True Range (ATR) | 0.11 | 0.43 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 5.07 | 62.13 |
Price Performance
Historical ComparisonAbout NFE New Fortress Energy Inc.
New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.